Physician profile
Pauline Schultz
NPI 1891797312
$3,418.83
in general payments reported to CMS, 2019-2025
14 companies · $494 in 2025
The $494 reported for 2025 was more than what 97% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $755 · 2022: $612 · 2023: $753 · 2024: $805 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,052.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,214.90 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Abbvie INC. | $624.05 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $554.71 | 2021-2024 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $287.43 | 2022-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $250.82 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $99.84 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $71.54 | 2023-2024 | Linzess |
| Evoke Pharma, INC. | $62.19 | 2021-2024 | Gimoti |
| Braintree Laboratories, INC. | $59.56 | 2022-2024 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $49.09 | 2024 | Dupixent |
| Mirum Pharmaceuticals, INC. | $44.20 | 2024 | Livmarli |
| Merck Sharp & Dohme LLC | $43.68 | 2021-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $33.01 | 2021 | |
| Aimmune Therapeutics, INC. | $23.81 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pauline Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.